
    
      The purpose of this study is to determine the safety, tolerability and pharmacokinetic
      profile of INNO-406 when administered as a daily oral agent in adult patients with
      imatinib-resistant or intolerant Philadelphia chromosome-positive (Ph+) leukemias.
    
  